Niki Biosolutions, Inc. is a nonprofit organization company, focused on cancer prevention, HIV/AIDS awareness and treatment support. The company is headquartered in London, England and currently employs 1 full-time employees. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The firm's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.
P/E (price / listing EPS) Forward revenue growth (NTM) 
